Open Interest and Volume Dynamics
On 24 March 2026, Glenmark’s open interest (OI) in derivatives rose sharply to 46,908 contracts from 39,453 the previous day, marking an increase of 7,455 contracts or 18.9%. This notable rise in OI was accompanied by a futures volume of 33,198 contracts, reflecting active participation from traders. The futures value stood at ₹1,60,519.66 lakhs, while the options segment exhibited a substantial notional value of ₹10,501.14 crores, culminating in a total derivatives market value of approximately ₹1,61,979.80 lakhs for Glenmark.
The underlying stock price closed at ₹2,087, having touched an intraday high of ₹2,137.10, a 2.3% rise during the session. However, the stock underperformed its sector by 1.27% and the broader Sensex by 1.77%, with a one-day return of -0.38% compared to the sector’s 1.03% gain. Notably, Glenmark has been on a two-day losing streak, shedding 4.41% cumulatively, indicating some near-term selling pressure despite the open interest build-up.
Market Positioning and Technical Context
The stock’s technical profile reveals a nuanced picture. Glenmark’s price remains above its 50-day, 100-day, and 200-day moving averages, signalling a longer-term uptrend. However, it trades below its 5-day and 20-day moving averages, suggesting short-term weakness and possible consolidation. This divergence often attracts speculative activity in derivatives as traders position for potential directional moves.
Investor participation appears to be waning, with delivery volumes on 23 March falling by 33.95% to 2.03 lakh shares compared to the five-day average. This decline in delivery volume indicates reduced conviction among long-term holders, possibly prompting increased speculative trading in the derivatives market to capitalise on volatility.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Interpreting the Open Interest Surge
The 18.9% increase in open interest is a clear indication that new positions are being established rather than existing ones being closed. This typically reflects growing interest and conviction among traders regarding the stock’s near-term direction. Given the recent price weakness and underperformance, the surge in OI could be attributed to both bullish and bearish bets, as market participants hedge or speculate on potential rebounds or further declines.
Options market data, with a notional value exceeding ₹10,500 crores, suggests significant activity in calls and puts, which often precedes volatility. The large open interest build-up in options can indicate that traders are positioning for a directional move or increased price swings, possibly anticipating upcoming corporate developments, sectoral news, or macroeconomic factors impacting pharmaceuticals and biotechnology.
Sector and Market Context
Glenmark operates within the Pharmaceuticals & Biotechnology sector, which has shown mixed performance recently. While the broader Sensex gained 1.77% on the day, Glenmark’s stock lagged, reflecting sector-specific challenges or company-specific concerns. The mid-cap classification with a market capitalisation of ₹58,728.81 crores places Glenmark in a segment where liquidity and volatility tend to be higher, attracting active derivatives trading.
The stock’s Mojo Score of 78.0 and a current Mojo Grade of Buy, downgraded from Strong Buy on 6 June 2025, indicate a positive but cautious outlook from MarketsMOJO’s analytical framework. This grading shift may have influenced traders’ positioning, as reflected in the derivatives market activity.
Curious about Glenmark Pharmaceuticals Ltd. from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Implications for Investors and Traders
The sharp rise in open interest alongside subdued price performance suggests a complex market sentiment. Traders may be employing strategies such as protective puts to hedge downside risk or call options to capitalise on potential rebounds. The divergence between short-term moving averages and longer-term averages further supports the likelihood of increased volatility and trading opportunities.
For investors, the falling delivery volumes and recent price declines warrant caution, signalling a possible short-term correction or consolidation phase. However, the stock’s sustained position above key long-term moving averages and a solid Mojo Score indicate underlying strength that could attract accumulation on dips.
Market participants should monitor upcoming earnings announcements, regulatory developments, and sectoral trends closely, as these factors could trigger directional moves reflected in derivatives activity. The current open interest surge may be an early indicator of such shifts, providing valuable insights for positioning.
Conclusion
Glenmark Pharmaceuticals Ltd.’s derivatives market activity reveals a significant build-up in open interest, signalling heightened trader interest amid a backdrop of recent price weakness and sector underperformance. The interplay of volume, open interest, and technical indicators suggests that market participants are positioning for potential volatility and directional moves in the near term. While the stock’s fundamentals and long-term technicals remain supportive, investors should remain vigilant to evolving market dynamics and use derivatives data as a complementary tool for informed decision-making.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
